SYK — Stryker Corporation stock price, charts and financials

QT30Stryker Corporation

Stryker Corporation (NYSE: SYK) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
275.39
-1.04-0.38%
SYKQT30Stryker Corporation·NYSE
275.39-0.38%
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500P/E28.54EPS (ttm)9.65Insider Own3.57%Shs Outstand383.36MPerf Week-13.24%
Market Cap105.57BForward P/E16.44EPS next Y16.75Insider Trans-4.93%Shs Float347.76MPerf Month-20.36%
Enterprise Value117.04BPEG2.51EPS next Q3.62Inst Own59.40%Short Float2.00%Perf Quarter-12.30%
Income3.73BP/S4.09EPS this Y55.61%Inst Trans0.00%Short Ratio2.63Perf Half Y-23.21%
Sales25.84BP/B4.40EPS next Y11.55%ROA7.78%Short Interest6.94MPerf YTD-21.65%
Book/sh62.57P/C30.37EPS next 5Y11.38%ROE16.36%52W High395.90 -30.44%Perf Year-29.95%
Cash/sh9.07P/FCF24.71EPS past 3/5Y10.83% 14.87%ROIC9.82%52W Low270.84 1.68%Perf 3Y-3.19%
Dividend Est.3.52 (1.28%)EV/EBITDA18.71Sales past 3/5Y10.83% 11.84%Gross Margin65.17%Volatility4.13% 3.00%Perf 5Y-0.62%
Dividend TTM3.48 (1.26%)EV/Sales4.53EPS Y/Y TTM24.36%Oper. Margin22.03%ATR (14)10.92Perf 10Y136.83%
Dividend Ex-DateSep 30, 2026Quick Ratio1.33Sales Y/Y TTM14.35%Profit Margin14.43%RSI (14)24.46Recom2.25
Dividend Gr. 3/5Y6.25% 7.62%Current Ratio2.16EPS Q/Q17.89%SMA20-14.54%Beta0.77Target Price371.65
Payout35.32%Debt/Eq0.73Sales Q/Q9.42%SMA50-15.70%Rel Volume2.13Prev Close276.43
Employees56,000LT Debt/Eq0.68EarningsOct 29SMA200-18.43%Avg Volume2.57MPrice275.39
IPO DateMar 17, 1980Option/ShortYes / YesEPS/Sales Surpr.5.78% 0.15%Net Debt/EBITDA1.85Volume5,473,725Change-0.38%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-09-26ReiteratedBMO CapitalOutperform$369$317
Sep-09-26ReiteratedWells FargoOverweight$286$348
Aug-13-26DowngradeWolfe ResearchOutperformPeer Perform
Jul-31-26ReiteratedRaymond JamesOutperform$383$370
Jul-31-26ReiteratedWolfe Research$375
Jul-31-26ReiteratedPiper SandlerOverweight$420$390
Jul-31-26ReiteratedBTIGBuy$371$358
Jul-31-26ReiteratedRBC CapitalOutperform$435$420
Jul-13-26ReiteratedBTIGBuy$379$371
Jul-09-26ReiteratedArgus ResearchBuy$350$370
Latest News· Times ET
Sep-09-26
Sep-08-26
Sep-07-26
Sep-04-26
Sep-03-26
Sep-01-26
Aug-31-26
Aug-30-26
Aug-29-26
Company

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

Ownership
Total institutional ownership59.40%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue25,83725,11622,595
Cost of Goods Sold Incl. D&A9,0009,0518,615
Gross Profit16,83716,06513,980
Selling, General and Administrative Excl. Other8,7828,6517,505
Research and Development1,6581,5821,414
Other Operating Expense7069430
Operating Income5,6914,8895,061
Interest Expense686607396
Unusual Expense
Non-Operating Income (Expense)143232-1,173
Net Income Before Taxes5,1484,5143,492
Income Taxes1,4191,268499
Consolidated Net Income3,7293,2462,993
Net Income From Continuing Operations3,7293,2462,993
Net Income3,7293,2462,993
EPS (Recurring)9.738.497.86
EPS (Basic, Before Extraordinaries)9.738.497.86
EPS (Diluted)9.658.407.76
EBITDA6,2556,3144,938
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio28.5441.8446.40
Price To Sales Ratio4.095.356.07
Gross Margin65.1763.9661.87
Operating Margin22.0319.4722.40
Net Margin14.4312.9213.25
Shares Outstanding384382381
Market Capitalization105,750134,262137,179
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$422.75$381.11$339.46$297.81$256.17 Close Price0.00M46.35M92.69M139.04M185.38MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BRAINERD MARY KDirectorNov 22 '22Buy225.19184,054131Sep 02
BRAINERD MARY KDirectorJun 12 '20Buy185.653557102Sep 02
BRAINERD MARY KDirectorMay 12 '20Buy193.21366,95699Sep 02
BRAINERD MARY KDirectorSep 12 '19Buy221.03112,4310Sep 02
BRAINERD MARY KDirectorJun 26 '19Buy202.216312,73963Sep 02
Crotty Dylan BramGroup PresidentAug 21 '26Sale328.61441144,9156,102Aug 26
STRYKER RONDA EDirectorAug 19 '26Sale340.1050,00017,005,1652,251,375Aug 20
STRYKER RONDA EDirectorAug 18 '26Sale335.90300,000100,770,9632,301,375Aug 20
King DebraSee RemarksAug 18 '26Sale336.30826277,7876,210Aug 18
Fletcher Robert SVP, Chief Legal OfficerMay 28 '26Sale306.874,5441,394,41010,582May 29
STRYKER RONDA EDirectorMay 26 '26Sale312.23310,00096,792,6691,924,880May 28
Fink M KathrynVP, Chief HR OfficerMay 11 '26Sale283.698,7202,473,756177May 12
Fink M KathrynVP, Chief HR OfficerMay 08 '26Option Exercise167.9821,5823,625,38834,719May 12
Menon VijuGroup PresidentMar 21 '26Option Exercise0.00269022,100Mar 24
Stiles Spencer SPresident and COOMar 21 '26Option Exercise0.00430084,324Mar 24
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.